MOR News and Press, MorphoSys AG From 07/28/22

Conference Call Alert PLANEGG and MUNICH, GERMANY / ACCESSWIRE / July 28, 2022 / MorphoSys AG (FSE:MOR); (NASDAQ:MOR) will publish its results for the second quarter and first half year 2022 results on August 3, 2022 at 10:00 pm CEST (9:00 pm BST; 4:00 pm EDT). MorphoSys' Management tea...

MorphoSys ( NASDAQ: MOR ) trades 12.8% down premarket after it provided updated financial guidance based on prelim consolidated results for the first six months 2022 and post the recent licensing agreements with Human Immunology Biosciences for felzartamab and MOR210....

Preliminary Q2 2022 Monjuvi U.S. net product sales of US$ 23.3 million (€ 21.7 million) Update of financial guidance range for 2022 Monjuvi U.S. net product sales (now US$ 90 to US$ 110 million) Update of R&D expense guidance (now € 275 to € 300 million) f...

Publication of an inside information according to Article 17 para. 1 of the Regulation (EU) No. 596/2014 Preliminary Q2 2022 Monjuvi U.S. net product sales of US$ 23.3 million (€ 21.7 million) Update of financial guidance ranges for 2022 Monjuvi U.S. net product sales (now ...

Unofficial sources said Joincare would seek to raise around $300 to $400 million. META Pharma of Shenzhen raised $15 million in Seed and Pre-A rounds to fund its immunometabolism-based small-molecule drug discovery operations. CANbridge, a Beijing-Cambridge MA rare disease/rare on...

I-Mab Partner MorphoSys Announces New License Agreements for Felzartamab and TJ210 PR Newswire SHANGHAI and GAITHERSBURG, Md. , June 15, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to...

Bulls are trying to battle back in the stock market today. While broader markets continue licking their wounds, those trading penny stocks are having just another day at the office. Why’s that? It doesn’t seem to matter if there’s a bear market, bull market, or sideways...

MorphoSys (NASDAQ:MOR) and U.S. biotech Human Immunology Bioscience (HIBio) have entered into licensing agreements to allow HIBio to develop and commercialize two of MorphoSys' antibodies. The antibodies are MorphoSys’ felzartamab, an anti-CD38 antibody, and MOR210, an anti-C5aR1 ...

Human Immunology Biosciences (HIBio) is a biotechnology company focused on developing precision medicines for autoimmune and inflammatory diseases, backed by ARCH Venture Partners and Monograph Capital HIBio obtains exclusive worldwide rights, with the exception of Gre...

Gainers: MorphoSys  (MOR) +20%. NGM Biopharmaceuticals (NGM) +14%. National Vision Holdings (EYE) +10%. Editas Medicine (EDIT) +10%. Hyzon Motors  (HYZN) +5%. Losers: Outset Medical (OM) -22%. Redbox Entertainment  (RDBXW) -14%. Xperi Holding Corporation (XPER) -7%. C...